Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

A legfontosabb adatok

Ki végzi
The University of Hong Kong
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
1861 fő vett részt
Kezdés
2017. okt. 7.
Befejezés
2025. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 11 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Standard inactivated influenza vaccine (NH formulation)
  • MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
  • High-dose inactivated influenza vaccine (NH formulation)
  • Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
A regiszteradat frissítve
2026. május 15.

Ki vehet részt

Életkor
65 év – 82 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult aged 65-82 years attending ECC and EDC who has not received 2017/18 seasonal influenza vaccine and is willing to receive annual influenza vaccination

Ki nem vehet részt

  • Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:; Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component, including egg protein; Moderate or severe acute illness with or without fever after any previous influenza vaccination; or; A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination
  • Individuals who show signs of dementia (do not pass the Mini-cog test under Appendix 1a: Recruitment Screening Log) or significant cognitive impairment and are not competent to give their consent
  • Individuals, who report medical conditions not suitable to receive intramuscular injection, such as:; bleeding disorders; habitually taking anticoagulants (with the exception of antiplatelets such as aspirin)
  • Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.

A vizsgálat 11 csoportja

  • Standard vaccineMár használt kezelés, összehasonlításként

    Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: Standard inactivated influenza vaccine (NH formulation)

  • Alternating standard vaccine & adjuvanted vaccineA vizsgált kezelés

    Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: Standard inactivated influenza vaccine (NH formulation) és MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Alternating adjuvanted vaccine & standard vaccineA vizsgált kezelés

    Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: Standard inactivated influenza vaccine (NH formulation) és MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Alternating standard vaccine and high-dose vaccineA vizsgált kezelés

    Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: Standard inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)

  • Alternating high-dose vaccine and standard vaccineA vizsgált kezelés

    Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: Standard inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)

  • Alternating adjuvanted vaccine and high-dose vaccineA vizsgált kezelés

    Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)

  • Alternating high-dose vaccine and adjuvanted vaccineA vizsgált kezelés

    Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) és High-dose inactivated influenza vaccine (NH formulation)

  • High-dose vaccineA vizsgált kezelés

    Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: High-dose inactivated influenza vaccine (NH formulation)

  • Adjuvanted vaccineA vizsgált kezelés

    Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Recombinant vaccineA vizsgált kezelés

    Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

  • Alternating recombinant vaccine and adjuvanted vaccineA vizsgált kezelés

    Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Kezelés: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) és Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial
Publikációk
A regiszteradat frissítve
2026. május 15.